These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35777619)

  • 21. Waitlist Outcomes for Exception and Non-exception Liver Transplant Candidates in the United States Following Implementation of the Median MELD at Transplant (MMaT)/250-mile Policy.
    Ishaque T; Beckett J; Gentry S; Garonzik-Wang J; Karhadkar S; Lonze BE; Halazun KJ; Segev D; Massie AB
    Transplantation; 2024 Aug; 108(8):e170-e180. PubMed ID: 38548691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. National Trends and Waitlist Outcomes of Locoregional Therapy Among Liver Transplant Candidates With Hepatocellular Carcinoma in the United States.
    Kwong AJ; Ghaziani TT; Yao F; Sze D; Mannalithara A; Mehta N
    Clin Gastroenterol Hepatol; 2022 May; 20(5):1142-1150.e4. PubMed ID: 34358718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-Effectiveness Analysis of Interventional Liver-Directed Therapies for a Single, Small Hepatocellular Carcinoma in Liver Transplant Candidates.
    Wu X; Heller M; Kwong A; Fidelman N; Mehta N
    J Vasc Interv Radiol; 2023 Jul; 34(7):1237-1246.e3. PubMed ID: 36804296
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequential transarterial chemoembolization and early radiofrequency ablation improves clinical outcomes for early-intermediate hepatocellular carcinoma in a 10-year single-center comparative study.
    Yan L; Ren Y; Qian K; Kan X; Zhang H; Chen L; Liang B; Zheng C
    BMC Gastroenterol; 2021 Apr; 21(1):182. PubMed ID: 33879085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors Associated With Complete Pathologic Necrosis of Hepatocellular Carcinoma on Explant Evaluation After Locoregional Therapy: A National Analysis Using the UNOS Database.
    Sarwar A; Bonder A; Hassan L; Malik MS; Novack V; Curry M; Ahmed M
    AJR Am J Roentgenol; 2023 May; 220(5):727-735. PubMed ID: 36475810
    [No Abstract]   [Full Text] [Related]  

  • 26. Survival advantage of radiofrequency ablation over transarterial chemoembolization for patients with hepatocellular carcinoma and good performance status within the Milan criteria.
    Liu PH; Lee YH; Hsu CY; Huang YH; Chiou YY; Lin HC; Huo TI
    Ann Surg Oncol; 2014 Nov; 21(12):3835-43. PubMed ID: 24903236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis.
    Lin CW; Chen YS; Lo GH; Hsu YC; Hsu CC; Wu TC; Yeh JH; Hsiao P; Hsieh PM; Lin HY; Shu CW; Hung CM
    BMC Gastroenterol; 2020 Apr; 20(1):99. PubMed ID: 32272898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effectiveness of locoregional therapies versus supportive care in maintaining survival within the Milan criteria in patients with hepatocellular carcinoma.
    Dhanasekaran R; Khanna V; Kooby DA; Spivey JR; Parekh S; Knechtle SJ; Carew JD; Kauh JS; Kim HS
    J Vasc Interv Radiol; 2010 Aug; 21(8):1197-204; quiz 204. PubMed ID: 20656222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria: a propensity score analysis.
    Hsu CY; Huang YH; Chiou YY; Su CW; Lin HC; Lee RC; Chiang JH; Huo TI; Lee FY; Lee SD
    Liver Transpl; 2011 May; 17(5):556-66. PubMed ID: 21506244
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemoembolization Combined with Radiofrequency Ablation for Medium-Sized Hepatocellular Carcinoma: A Propensity-Score Analysis.
    Chu HH; Kim JH; Yoon HK; Ko HK; Gwon DI; Kim PN; Sung KB; Ko GY; Kim SY; Park SH
    J Vasc Interv Radiol; 2019 Oct; 30(10):1533-1543. PubMed ID: 31471190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma.
    Ni JY; Liu SS; Xu LF; Sun HL; Chen YT
    World J Gastroenterol; 2013 Jun; 19(24):3872-82. PubMed ID: 23840128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early Stage Hepatocellular Carcinomas Not Feasible for Ultrasound-Guided Radiofrequency Ablation: Comparison of Transarterial Chemoembolization Alone and Combined Therapy with Transarterial Chemoembolization and Radiofrequency Ablation.
    Hyun D; Cho SK; Shin SW; Park KB; Park HS; Choo SW; Do YS; Choo IW; Lee MW; Rhim H; Lim HK
    Cardiovasc Intervent Radiol; 2016 Mar; 39(3):417-25. PubMed ID: 26246215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radiofrequency Ablation Following Downstaging of Hepatocellular Carcinoma by Using Transarterial Chemoembolization: Long-term Outcomes.
    Shi F; Wu M; Lian SS; Mo ZQ; Gou Q; Xu RD; Li HL; Huang ZM; Wu PH; Chen XM
    Radiology; 2019 Dec; 293(3):707-715. PubMed ID: 31638492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Mandatory 6-Month Waiting Period on Waitlist and Transplant Outcomes in Patients With Hepatocellular Carcinoma.
    Nagai S; Kitajima T; Yeddula S; Salgia R; Schilke R; Abouljoud MS; Moonka D
    Hepatology; 2020 Dec; 72(6):2051-2062. PubMed ID: 32157711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of transarterial chemoembolization compared with radiofrequency ablation for the treatment of recurrent hepatocellular carcinoma after radiofrequency ablation.
    Wang X; Liang H; Lu Z
    Minim Invasive Ther Allied Technol; 2020 Dec; 29(6):344-352. PubMed ID: 31375044
    [No Abstract]   [Full Text] [Related]  

  • 37. Locoregional therapy and recurrence of hepatocellular carcinoma after liver transplant.
    Kırnap M; Boyvat F; Akdur A; Karakayalı F; Arslan G; Moray G; Haberal M
    Exp Clin Transplant; 2014 Mar; 12 Suppl 1():166-9. PubMed ID: 24635819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radiofrequency ablation combined with transarterial chemoembolization versus hepatectomy for patients with hepatocellular carcinoma within Milan criteria: a retrospective case-control study.
    Bholee AK; Peng K; Zhou Z; Chen J; Xu L; Zhang Y; Chen M
    Clin Transl Oncol; 2017 Jul; 19(7):844-852. PubMed ID: 28070766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radiofrequency ablation combined with transarterial chemoembolization in treatment of hepatocellular carcinoma adjacent to the second hepatic hilus.
    Chen ML; Li HL; Guo CY; Zhang H; Yuan H; Li Z; Park JH; Hu HT
    Abdom Radiol (NY); 2022 Jan; 47(1):423-430. PubMed ID: 34635940
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis.
    Majumdar A; Roccarina D; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011650. PubMed ID: 28351116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.